drugset / Trial / NCT07661173
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC
Timeline
- Start
- 2026-06-06
- Primary completion
- 2029-03-06
- Completion
- 2031-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Firmonertinib | Small molecule | 80 mg | Oral |
| Subject | Pemetrexed | Small molecule | — | — |